We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1-Infected Subjects.
- Authors
Kuritzkes, Daniel R.; Lalama, Christina M.; Ribaudo, Heather J.; Marcial, Michelle; Meyer III, William A.; Shikuma, Cecilia; Johnson, Victoria A.; Fiscus, Susan A.; D'Aquila, Richard T.; Schackman, Bruce R.; Acosta, Edward P.; Gulick, Roy M.
- Abstract
A case-cohort study was used to determine the effect of baseline nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance, as assessed by viral genotyping, on the response to efavirenz-containing regimens in AIDS Clinical Trials Group A5095. The sample included a random cohort of efavirenz-treated subjects plus unselected subjects who experienced virologic failure. Of 220 subjects in the random cohort, 57 (26%) had virologic failure. The prevalence of baseline NNRTI resistance was 5%. The risk of virologic failure for subjects with baseline NNRTI resistance was higher than that for subjects without such resistance (hazard ratio 2.27 [95% confidence interval], 1.15-4.49; P = .018). These results support resistance testing before starting antiretroviral therapy.
- Subjects
HIV; HIV infections; NATURAL immunity; ANTIRETROVIRAL agents; VIRUS disease drug therapy; CLINICAL medicine; VIRUS inhibitors; PREVENTIVE medicine; CLINICAL trials
- Publication
Journal of Infectious Diseases, 2008, Vol 197, Issue 6, p867
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1086/528802